Veracity Capital LLC Invests $589,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Veracity Capital LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,191 shares of the medical research company’s stock, valued at approximately $589,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Wellington Management Group LLP lifted its stake in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares during the last quarter. Earnest Partners LLC boosted its stake in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Charles River Laboratories International by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock valued at $101,483,000 after acquiring an additional 32,311 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on CRL. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Finally, Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $204.38.

Charles River Laboratories International Trading Down 0.9 %

NYSE CRL opened at $166.75 on Friday. Charles River Laboratories International, Inc. has a one year low of $160.85 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $8.53 billion, a price-to-earnings ratio of 20.87, a price-to-earnings-growth ratio of 5.97 and a beta of 1.38. The company’s 50-day simple moving average is $187.21 and its two-hundred day simple moving average is $197.51.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company posted $2.72 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).